Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024

PR NewswireNov 17 07:30 ET

Carisma Therapeutics Is Maintained at Buy by D. Boral Capital

Dow JonesNov 11 17:20 ET · Ratings

Carisma Therapeutics Price Target Maintained With a $24.00/Share by D. Boral Capital

Dow JonesNov 11 17:20 ET · Ratings

Optimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial Standing

TipRanksNov 11 01:15 ET · Ratings

Evercore Maintains Carisma Therapeutics(CARM.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 8 09:38 ET · Ratings

Evercore ISI Remains a Buy on Carisma Therapeutics (CARM)

TipRanksNov 8 09:19 ET · Ratings